

**REMARKS**

Entry of the foregoing, pursuant to and consistent with 37 C.F.R. § 1.312, is respectfully requested.

The Examiner's Amendment attached to the Notice of Allowability regarding the paragraph on page 4 of the specification at lines 28-30 contained what appears to be a typographical error. In particular, the last sentence of the paragraph should have recited that the cDNAs were treated with, *inter alia*, exonuclease III - not exonuclease I. The Examiner's attention is directed to Example 12, and in particular page 26, lines 19-22, which shows that the exonuclease used was exonuclease III. Therefore, by the foregoing amendment, the specification has been amended to correct this inadvertent error by the Examiner. Such amendment does not add new matter, does not change the scope of the claims, does not require additional search, and does not involve materially added work on the part of the United States Patent and Trademark Office.


In the event that there are any questions relating to this Amendment Under 37 C.F.R. § 1.312, or the application in general, it would be appreciated if the Examiner would

telephone the undersigned attorney concerning such questions so that prosecution of this application may be expedited.

Respectfully submitted,

BUCHANAN INGERSOLL PC  
Including attorneys from Burns, Doane, Swecker & Mathis

Date: January 17, 2006

By:   
Susan M. Dadio  
Registration No. 40,373

P.O. Box 1404  
Alexandria, Virginia 22313-1404  
(703) 836-6620